A new study published in Drug and Alcohol Review has revealed critical insights into the challenges and risks faced by women who use anabolic-androgenic steroids (AAS).
Astellas stops developing autologous cell therapy using tech from Xyphos buyout
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS